Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

ClinOne’s BYOD ePRO Helps Achieve Zero Data Loss for Clinical Trial Sites Globally

Published

on

Reading Time: 3 minutes

DENVER–(BUSINESS WIRE)–Having recently been named to the Top 10 eClinical Companies for 2019 by Pharma
Tech Outlook Magazin
e, ClinOne brings substantial
benefits to clinical trials with its BYOD ePRO module. The main,
overarching benefit: zero data loss.

Adoption of BYOD (Bring Your Own Device) ePRO in clinical trials has
been measured due to regulatory, security and technical concerns. Now
that these concerns have been addressed and regulatory bodies have
approved, sponsors and CROs are diving in. Now, there’s an even more
beneficial reason to bring your trial into the BYOD world, and that’s your
data
.

The Good News

Site sponsors benefit from the use of BYOD ePRO because of the reduced
cost over hardware-derived ePRO solutions, as well as significantly
reducing the site burden of having to allocate and deal with provisioned
devices. The more remarkable value and ultimate cost savings lie in
knowing that without the third-party devices which other clinical trial
sites outside of ClinOne use, being allowed to use their own devices,
patients will experience very minuscule to virtually zero data loss.
This positively affects the bottom line for sites and sponsors,
ultimately, avoiding loss of data which can disqualify patients,
incurring re-enrollment costs to the site. Viewed more holistically, we
can say that this means that data loss being eliminated, the risk of a
trial’s retention rates decreasing, or enrollments being stalled or
extended for a longer period of time – costing additional trial dollars
– is taken out of the equation.

Getting Down to Brass Tacks

ClinOne’s BYOD ePRO can reduce PRO costs by as much as 75% over the cost
of paper (mainly the hidden costs) and 65% or more over existing
hardware-based providers. ClinOne’s fully validated, regulatory
compliant ePRO solution is part of the ClinTrialConnect suite of
patient-facing technologies. Patients can access, complete, review and
sign their diaries or questionnaires electronically, utilizing DocuSign,
all through the ClinTrialConnect patient portal, and exported to the
sponsor’s preferred EDC vendor. Patients and sites automatically receive
a completed version of the signed questionnaire to add to their EHR.
“Research has shown that 86% of patients prefer ePRO to traditional
reporting and diary entry,” according to Chris Watson, MD, PhD and
Director of Product Strategy, Digital Patient, at ERT1.

Our ePRO module can eliminate the major issue of data loss which
presents itself and causes such issues as highlighted by
Mercieca-Bebber, et al: “High rates of missing PRO data can reduce study
power, inflate risk of type 2 error, bias interpretation, and
potentially undermine randomization.”2

A review of 36 ovarian cancer trials in this same report, showed that a
full “41% of trial participants had avoidable missing data (not
illness-related),3” which extremely affects the integrity of
the critical results for these trials.

Invaluable Addition to an Already Multi-capable Platform

“Utilizing ClinOne’s ePRO solution for the appropriate trials can lead
to significant cost-savings, particularly for those trials requiring
routine diary entries, over several months or years,” Rob Bohacs, CEO
and co-founder, states. “We are also planning a wearable sensor
integration in Q3 2019, which will allow correlation of data between
ePRO and live sensor data – an industry first.” Now, with the added
benefit of zero data loss, sites and sponsors can be assured that their
patients have a much stronger chance of remaining compliant throughout
the entire trial, allowing them to rely on all on-boarded patients,
having a much higher retention rate, altogether. You can see how this
translates into making the use of BYOD ePRO for all trials well worth
the investment.


1. Watson, Chris, “Increase Clinical Trial Patient Engagement and
Compliance with ePRO,” ERT.com, June 26, 2018.

2, 3. Mercieca-Bebber, Rebecca; King, Madeleine; Calvert, Melanie;
Stockler, Martin; Friedlander, Michael, “The importance of patient
reported outcomes in clinical trials and strategies for future
optimization.” Patient Related Outcome Measures, 2018:9, 353-357.

About ClinOne

ClinOne offers a complete suite of mobile and web applications to
enhance patient, family, caregiver and site engagement. Currently, our
solutions help support close to 3,000 clinical studies, across 1,900
research sites in 54 countries. If you are interested in learning more
or scheduling a demo, contact us. Visit www.clinone.com
for more information.

Contacts

Christine Oneto
[email protected]
415.676.1662

Rob
Bohacs
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III

Published

on

Continue Reading

Humboldt

Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace

Published

on

humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace

Apollo Green to distribute Humboldt Seed Company clonal cannabis genetics to Germany, Portugal and Australia

SAN FRANCISCO, April 30, 2024 /PRNewswire/ — Humboldt Seed Company (HSC), California’s leading cannabis seed producer, has announced a partnership with Canadian-based Apollo Green to make eight breeder cuts available to researchers, licensed commercial cultivators and home growers in legal markets worldwide. This first-to-market clonal genetics release is a significant milestone and will expand access to distinctive, high-quality cannabis genetics in both established and emerging global markets including Germany, Portugal and Australia.

The curated, breeder-verified selection includes pioneering triploid genetics, such as OG Triploid and Donutz Triploid alongside the legendary cult classic Blueberry Muffin. Also available are All Gas OG with a THC content of 21% and four high-THC strains in the 30-35% range: Golden Sands, Guzzlerz, Jelly Donutz and Orange Creampop. These selections represent the top .01% from HSC’s extensive California pheno-hunting program.

Exports will begin in May under Apollo Green’s Canadian federal cannabis license. All shipments have Canadian phytosanitary certification, ensuring plants have been inspected, and are clean and free of pests.

“Access for all to quality genetics has been our core focus since the beginning,” said HSC Co-founder and Chief Science Officer, Benjamin Lind. “Our science-based approach to breeding aligns perfectly with Apollo Green’s high standards and we are excited to be able to extend these hand-selected cuts to a wider audience, especially at this pivotal time where we’re seeing positive regulatory changes globally.”

Oisin Tierney, Apollo Green Director of Business Development, said, “California has long been recognized for setting industry standards, and we are proud to play a role in bringing these esteemed genetics to cultivators worldwide. The triploids are especially noteworthy in terms of the unprecedented potential for enhanced plant vigor, higher yields, shorter flowering times and superior returns for solventless extraction.”

About Humboldt Seed Company

Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets including Spain, Canada, Jamaica, South Africa, Colombia, France, Portugal, Greece, the UK, Malta and Thailand. With a focus on environmental and social justice, they combine traditional breeding and modern scientific practices in their strain development program. They have served the cannabis community for over two decades.

For more information visit https://humboldtseedcompany.com/.

About Apollo Green

Licensed since 2019, Apollo Green is Canada’s leader in cannabis genetics. The company’s mission is to provide an ever-growing bank of seeds and clones to medical patients and recreational consumers. Apollo Green provides clean, trusted cannabis seeds and clones, which are backed by the foremost tissue culture technology to reduce risks, costs and time-to-market for licensed producers around the world. Apollo Green is passionate about cannabis genetics. 

For more information visit https://apollogreen.com/.

Media contact
Jaana Prall
[email protected] 

Logo – https://mma.prnewswire.com/media/2328955/Humboldt_Seed_Company_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace-302131618.html

Continue Reading

Cannabis

Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania